Details of the Drug Combination

General Information of Drug Combination (ID: DCUMQL3)

Drug Combination Name
MK-4815 Sarpogrelate
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs MK-4815   DMT9K74 Sarpogrelate   DMGLP6S
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 7.108
Bliss Independence Score: 11.381
Loewe Additivity Score: 0.659
LHighest Single Agent (HSA) Score: 4.347

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of MK-4815
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [2]
Indication(s) of Sarpogrelate
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Approved [3]
Sarpogrelate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Antagonist [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
DD2 DCO8QME DD2 Investigative [5]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 210).
4 Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
5 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966